Anna Cyranka, PhD, currently Vice President Program and Alliance at Alvotech – Icelandic biotech company focusing on biosimilars development. Responsible for strategies and oversight of the portfolio in alignment with commercial partners needs. Before that she spent 9 years with Polpharma biologics, building the team and being part of the first successful biosimilar application from Poland (ranibizumab – approved both in EU and US). More than 12 years’ experience in managing drug development programs, both in pharma and biotech start-ups. She earned her PhD at ETH Zurich / University of Wroclaw, and MBA from Gdansk University of Technology. Dynamic biopharma leader keen on progressive initiatives, translating biotech science into patients’ lives.